Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Actinogen Medical ( (AU:ACW) ) has issued an update.
Actinogen Medical Limited has announced its 2025 Annual General Meeting (AGM) of Shareholders, scheduled to take place in person on November 19, 2025, at K&L Gates in Sydney. Shareholders are encouraged to lodge their proxy forms online, as hard copies of the meeting notice will not be sent unless specifically requested. This move aligns with recent legislative changes and reflects the company’s commitment to digital communication, potentially enhancing shareholder engagement and operational efficiency.
More about Actinogen Medical
Actinogen Medical Limited operates in the biotechnology industry, focusing on the development of innovative therapies for neurological and neuropsychiatric diseases. The company is primarily engaged in advancing its lead compound, Xanamem, which targets cognitive impairment associated with neurological conditions.
Average Trading Volume: 2,554,642
Technical Sentiment Signal: Hold
Current Market Cap: A$98.44M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.